Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported that China has approved Pfizer Inc. (NYSE:PFE)’s GLP-1 treatment Xianweiying ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Chris Boshoff has had a busy first year as CSO and President of R&D at Pfizer. First, there were the organizational changes. Boshoff, the company’s previous chief oncology officer, joined Pfizer in ...

It’s rare to get such a massive high-yielder that’s also positioning itself for long-term growth. Of course, shares of Pfizer ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...

The annual tick report shows Lone Star ticks have established populations along Connecticut's shoreline, raising the risk of ...

Months after it agreed to hold off on raising prices following heavy pressure from President Trump, Pfizer now says it will increase the prices of 41 drugs in January. The pharmaceutical giant says ...

Pfizer has reached a turning point.

TrumpRx/MFN pricing risks could pressure margins despite 9.3x fwd P/E, 6.27% dividend and pipeline gains. Read the latest ...